- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
Setting: Community
A research environment where studies are conducted outside of clinical or laboratory settings, focusing on real-world populations
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Blood sample
- Adults (18-64 years)
- Elderly (≥65 years)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- SARS-CoV-2
- Nasopharyngeal swab
- Non pharmacological intervention
- Elderly (≥65 years)
- Fragile population
- Outpatient clinic
- Community
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Molnupiravir
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Hospital
- Outpatient clinic
- Community
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Community
- Primary care
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- Community
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- Community
- Primary care
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Pharmacological intervention
- Nitric Oxide Nasal Spray